• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

合成抗凝血酶III结合五糖与标准肝素作为冠状动脉溶栓辅助药物的比较。

Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.

作者信息

Pislaru S V, Pislaru C, Zhu X, Arnout J, Stassen T, Vanhove P, Herbert J M, Meuleman D G, Van de Werf F

机构信息

Department of Cardiology, University Hospitals Leuven, Belgium.

出版信息

Thromb Haemost. 1998 Jun;79(6):1130-5.

PMID:9657437
Abstract

The effects on alteplase-induced thrombolysis of the synthetic ATIII-binding pentasaccharide SR90107A/ORG 31540 (synthetic pentasaccharide, SP) and of standard heparin (SH) were compared in a copper coil model of coronary artery thrombosis in 6 groups of 10 dogs. After 1 h of occlusion, all animals received intravenously alteplase and aspirin, and were randomly assigned to a 2 h infusion of either saline, or one of two doses of SH (100 IU/kg bolus plus 50 IU/kg/h infusion, or 200 IU/kg bolus plus 100 IU/kg/h infusion), or one of three doses of SP (100 nmol/kg bolus plus 50 nmol/kg/h infusion, 200 nmol/kg bolus plus 100 nmol/kg/h infusion, or 400 nmol/kg bolus plus 200 nmol/kg/h infusion). Coronary angiography was performed every 10 min for 4 h. Appropriate doses of SP and SH enhanced alteplase-induced thrombolysis to a similar extent. In contrast, SP was devoid of any anti-IIa activity or aPTT prolongation.

摘要

在6组每组10只犬的冠状动脉血栓形成铜线圈模型中,比较了合成的抗凝血酶III(ATIII)结合五糖SR90107A/ORG 31540(合成五糖,SP)和标准肝素(SH)对阿替普酶诱导溶栓的影响。闭塞1小时后,所有动物静脉注射阿替普酶和阿司匹林,并随机分配接受2小时的生理盐水输注,或两种剂量的SH之一(100 IU/kg推注加50 IU/kg/h输注,或200 IU/kg推注加100 IU/kg/h输注),或三种剂量的SP之一(100 nmol/kg推注加50 nmol/kg/h输注,200 nmol/kg推注加100 nmol/kg/h输注,或400 nmol/kg推注加200 nmol/kg/h输注)。在4小时内每10分钟进行一次冠状动脉造影。适当剂量的SP和SH在相似程度上增强了阿替普酶诱导的溶栓作用。相比之下,SP没有任何抗IIa活性或活化部分凝血活酶时间(aPTT)延长。

相似文献

1
Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis.合成抗凝血酶III结合五糖与标准肝素作为冠状动脉溶栓辅助药物的比较。
Thromb Haemost. 1998 Jun;79(6):1130-5.
2
Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.低分子量肝素(那屈肝素钙)与普通肝素作为阿替普酶和阿司匹林辅助药物用于犬冠状动脉溶栓的比较
Coron Artery Dis. 1995 Mar;6(3):257-63.
3
Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.在狭窄犬冠状动脉中使用rtPA溶栓期间,依诺肝素、希美加群和肝素作为辅助抗血栓治疗的比较。
Thromb Haemost. 1997 Oct;78(4):1278-85.
4
Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
J Am Coll Cardiol. 1993 Sep;22(3):914-20. doi: 10.1016/0735-1097(93)90211-i.
5
Comparison of desulfatohirudin (REVASC) and heparin as adjuncts to thrombolytic therapy with reteplase in a canine model of coronary thrombosis.在犬冠状动脉血栓形成模型中,硫酸皮肤素水蛭素(REVASC)与肝素作为瑞替普酶溶栓治疗辅助药物的比较。
Br J Pharmacol. 1996 May;118(2):271-6. doi: 10.1111/j.1476-5381.1996.tb15398.x.
6
In vivo effects of contrast media on coronary thrombolysis.造影剂对冠状动脉溶栓的体内效应。
J Am Coll Cardiol. 1998 Oct;32(4):1102-8. doi: 10.1016/s0735-1097(98)00326-x.
7
Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis.在冠状动脉溶栓过程中,阿司匹林不会增强次优剂量凝血酶抑制剂依诺加群的效果。
Cardiovasc Res. 1995 Dec;30(6):866-74.
8
A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.一种新型凝血因子Xa合成抑制剂可降低犬冠状动脉纤溶后的早期再闭塞率,并改善24小时通畅率。
J Pharmacol Exp Ther. 2001 Feb;296(2):567-72.
9
Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs.依诺肝素和肝素对犬动脉和静脉血栓与阿替普酶联合溶栓的比较效应。
Thromb Haemost. 1993 May 3;69(5):454-9.
10
Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.新型Xa因子抑制剂FXV673在犬冠状动脉溶栓模型中的抗血栓形成疗效。
Br J Pharmacol. 2001 Aug;133(7):1190-8. doi: 10.1038/sj.bjp.0704182.

引用本文的文献

1
2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.2022 年兽医重症监护领域抗栓和溶栓药物合理应用共识更新(CURATIVE)第六域:定义溶栓药物的合理应用。
J Vet Emerg Crit Care (San Antonio). 2022 Jul;32(4):446-470. doi: 10.1111/vec.13227.
2
Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study.静脉血栓形成中血液对纤维蛋白的可及性取决于血栓年龄并可预测纤溶效果:一项体内纤维蛋白分子成像研究。
Theranostics. 2015 Sep 13;5(12):1317-27. doi: 10.7150/thno.12494. eCollection 2015.
3
Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
重组人微栓酶在犬冠状动脉铜线圈致血栓模型中的溶栓疗效。
J Thromb Thrombolysis. 2010 Jul;30(1):46-54. doi: 10.1007/s11239-009-0400-9.
4
Novel inhibitors of factor X for use in cardiovascular diseases.用于心血管疾病的新型X因子抑制剂。
Curr Cardiol Rep. 2000 Sep;2(5):395-404. doi: 10.1007/s11886-000-0052-z.